1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 89,61 | -0,13 % | Gilead Sciences-Aktie: Trump als Kurs-Killer | Die US-Börsen feiern zum Wochenbeginn die Deeskalation im Handelskonflikt zwischen den USA und China. Aber Pharmawerte wie die Gilead Sciences-Aktie gehören zu den Verlierern in diesem sehr positiven... ► Artikel lesen | |
| ZOETIS | 142,70 | -0,46 % | BTIG maintains Buy on Zoetis stock with $200 target | ||
| INCYTE | 55,88 | -0,43 % | Aktie von Incyte: Kurs nur geringfügig im Minus (52,6904 €) | Die Wertschätzung für den Anteilsschein von Incyte hat sich am Aktienmarkt heute kaum geändert. Die Aktie notiert aktuell bei 59,37 US-Dollar. Die Wertschätzung der Investoren für die Aktie von Incyte... ► Artikel lesen | |
| AMARIN | 8,850 | -5,85 % | AMARIN CORP PLC - 8-K, Current Report | ||
| CASSAVA SCIENCES | 1,842 | +0,74 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 97,00 | +4,86 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,250 | -2,39 % | Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program | Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 253,40 | -2,80 % | Madrigal's liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis | ||
| SEELOS THERAPEUTICS | 2,000 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,071 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| TALPHERA | 0,446 | -2,20 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 17,700 | +0,57 % | Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update | First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 54,00 | +1,89 % | ANI Pharmaceuticals, Inc. Q1 Profit Decreases, But Beats Estimates | WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) reported earnings for first quarter that decreased from the same period last year but beat the Street estimates.The company's bottom line... ► Artikel lesen | |
| SAVARA | 2,680 | -3,60 % | Savara GAAP EPS of -$0.12 beats by $0.01 | ||
| MOLECULAR TEMPLATES | 0,107 | -0,56 % | Molecular Templates, Inc.: Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules | AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen |
CORNERSTONE THERAPEUTICS INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.